{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:23:32Z","timestamp":1782231812455,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.leukres.2025.108117","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:00:14Z","timestamp":1760500814000},"page":"108117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world treatment patterns and clinical outcomes of patients with treatment-na\u00efve and relapsed\/refractory diffuse large B-cell lymphoma in the United States"],"prefix":"10.1016","volume":"159","author":[{"given":"Jennifer K.","family":"Lue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-8314","authenticated-orcid":false,"given":"Priyanka J.","family":"Bobbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahek","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9269-7416","authenticated-orcid":false,"given":"Christopher W.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1749-7880","authenticated-orcid":false,"given":"Katherine E.","family":"Ryland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2025.108117_bib1","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by world health organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.leukres.2025.108117_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2025.108117_bib3","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: NHL \u2014 Diffuse large B-cell lymphoma (DLBCL). Accessed November 9, 2023. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html\u3009."},{"issue":"6","key":"10.1016\/j.leukres.2025.108117_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061453","article-title":"DLBCL 1L-What to expect beyond R-CHOP?","volume":"14","author":"Stegemann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2025.108117_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.leukres.2025.108117_bib6","first-page":"67","article-title":"Polatuzumab vedotin for the Front-Line treatment of diffuse large B-Cell lymphoma: a new standard of care?","volume":"14","author":"Davis","year":"2023","journal-title":"J. Adv. Pr. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2025.108117_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-Cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.leukres.2025.108117_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.leukres.2025.108117_bib9","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2025.108117_bib10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23524","article-title":"Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era","volume":"88","author":"Nagle","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.108117_bib11","unstructured":"US Food and Drug Administration (FDA). FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. Updated October 18, 2017. Accessed November 29, 2023. \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma\u3009."},{"key":"10.1016\/j.leukres.2025.108117_bib12","unstructured":"BREYANZI (lisocabtagene maraleucel) prescribing information. June 2023."},{"key":"10.1016\/j.leukres.2025.108117_bib13","unstructured":"YESCARTA (axicabtagene ciloleucel) prescribing information. November 2022."},{"issue":"9","key":"10.1016\/j.leukres.2025.108117_bib14","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.leukres.2025.108117_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang","year":"2021","journal-title":"J. Immunother. Precis Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108117_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"10.1016\/j.leukres.2025.108117_bib17","unstructured":"MONJUVI (tafasitamab-cxix) prescribing information. June 2021."},{"key":"10.1016\/j.leukres.2025.108117_bib18","unstructured":"XPOVIO (selinexor) prescribing information. June 2020."},{"key":"10.1016\/j.leukres.2025.108117_bib19","unstructured":"POLIVY (polatuzumab vedotin-piiq) prescribing information. April 2023."},{"key":"10.1016\/j.leukres.2025.108117_bib20","unstructured":"ZYNLONTA (loncastuximab tesirine-lpyl) prescribing information. October 2022."},{"key":"10.1016\/j.leukres.2025.108117_bib21","unstructured":"Lymphoma Research Foundation. Diffuse large B-cell lymphoma: FDA updates. Accessed November 29, 2023. \u3008https:\/\/lymphoma.org\/understanding-lymphoma\/aboutlymphoma\/nhl\/dlbcl\/dlbclfdaupdates\/#:\u223c:text=More%20information.,more%20lines%20of%20systemic%20therapy\u3009."},{"issue":"4","key":"10.1016\/j.leukres.2025.108117_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinthera.2022.02.004","article-title":"Burden of illness and treatment patterns in second-line large B-cell lymphoma","volume":"44","author":"Snider","year":"2022","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.leukres.2025.108117_bib23","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/03007995.2021.1957806","article-title":"Characteristics and treatment patterns of relapsed\/refractory diffuse large B-cell lymphoma in patients receiving >\/=3 therapy lines in post-CAR-T era","volume":"37","author":"Xie","year":"2021","journal-title":"Curr. Med Res Opin."},{"issue":"4","key":"10.1016\/j.leukres.2025.108117_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/fon-2020-0522","article-title":"Real-world practice patterns and outcomes in veterans with relapsed\/refractory diffuse large B-cell lymphoma","volume":"17","author":"Chien","year":"2021","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2025.108117_bib25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/fon-2018-0788","article-title":"Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA","volume":"15","author":"Morrison","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.leukres.2025.108117_bib26","unstructured":"Anderson S. COTA and Panalgo Q&A. \u3008https:\/\/cotahealthcare.com\/cota-and-panalgo-qa\/\u3009."},{"issue":"ement 1","key":"10.1016\/j.leukres.2025.108117_bib27","article-title":"Validation of a composite Real-World mortality variable among patients with hematologic malignancies treated in the United States","volume":"142","author":"Dong","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.108117_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.2023023789","article-title":"The current landscape of frontline large B-cell lymphoma trials","volume":"145","author":"Qualls","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2025.108117_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.seminhematol.2023.12.001","article-title":"Second-line treatment of diffuse large B-cell lymphoma: evolution of options","volume":"60","author":"Fabbri","year":"2023","journal-title":"Semin Hematol."},{"issue":"19","key":"10.1016\/j.leukres.2025.108117_bib30","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2025.108117_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2025.108117_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2217\/fon-2023-0191","article-title":"Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma","volume":"20","author":"Garg","year":"2024","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108117_bib33","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1002\/onco.13721","article-title":"Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.leukres.2025.108117_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7173","article-title":"Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy","volume":"13","author":"Sineshaw","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.leukres.2025.108117_bib35","unstructured":"FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. 2022. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma\u3009."},{"issue":"12","key":"10.1016\/j.leukres.2025.108117_bib36","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.7326\/M22-2276","article-title":"Second-Line chimeric antigen receptor T-Cell therapy in diffuse large B-Cell lymphoma: a Cost-Effectiveness analysis","volume":"176","author":"Kelkar","year":"2023","journal-title":"Ann. Intern Med"},{"issue":"8","key":"10.1016\/j.leukres.2025.108117_bib37","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1080\/10428194.2017.1406085","article-title":"Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2025.108117_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3325\/cmj.2017.58.40","article-title":"Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients","volume":"58","author":"Pejsa","year":"2017","journal-title":"Croat. Med J."},{"issue":"2","key":"10.1016\/j.leukres.2025.108117_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3960\/jslrt.23001","article-title":"Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma","volume":"63","author":"Haeno","year":"2023","journal-title":"J. Clin. Exp. Hematop"},{"issue":"3","key":"10.1016\/j.leukres.2025.108117_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm. Med"},{"issue":"16_","key":"10.1016\/j.leukres.2025.108117_bib41","article-title":"Real-world outcomes with novel therapies in R\/R DLBCL","volume":"41","author":"Crombie","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.108117_bib42","unstructured":"US Food and Drug Administration (FDA). FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-previously-untreated-diffuse-large-b-cell-lymphoma-not\u3009."},{"key":"10.1016\/j.leukres.2025.108117_bib43","unstructured":"US Food and Drug Administration (FDA). FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. \u3008https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell\u3009."},{"key":"10.1016\/j.leukres.2025.108117_bib44","unstructured":"US Food and Drug Administration (FDA). FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. \u3008https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell\u3009."},{"key":"10.1016\/j.leukres.2025.108117_bib45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/OTT.S372783","article-title":"Targeted treatment of adults with relapsed or refractory diffuse large B-Cell lymphoma (DLBCL): tafasitamab in context","volume":"16","author":"Abdulhaq","year":"2023","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.leukres.2025.108117_bib46","doi-asserted-by":"crossref","DOI":"10.21037\/aol-22-3","article-title":"Age is just a number: managing relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in older patients","volume":"6","author":"Wallace","year":"2022","journal-title":"Ann. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:26:55Z","timestamp":1773815215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"alternative-id":["S0145212625006071"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108117","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and clinical outcomes of patients with treatment-na\u00efve and relapsed\/refractory diffuse large B-cell lymphoma in the United States","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108117"}}